Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications
- PMID: 40820071
- DOI: 10.1007/s12094-025-04019-4
Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications
Abstract
Cancer is a complex and heterogeneous disease driven by a multitude of genetic alterations, including mutations, chromosomal rearrangements, and epigenetic modifications. Advances in genomic technologies have significantly enhanced our understanding of the genetic landscape of cancer, enabling the identification of key oncogenes, tumor suppressor genes, and DNA repair mechanisms that influence tumor progression. This review examines the molecular mechanisms underlying cancer development, focusing on the roles of mutations in genes such as TP53, KRAS, and EGFR. Furthermore, it explores the implications of genomic instability, tumor microenvironment interactions, and the emergence of precision medicine in oncology. The integration of next-generation sequencing and bioinformatics has facilitated the discovery of novel therapeutic targets, paving the way for personalized treatment strategies. Despite these advancements, challenges remain, including treatment resistance, tumor heterogeneity, and ethical considerations in genetic research. Addressing these complexities requires a multidisciplinary approach that combines molecular biology, bioinformatics, and clinical research. This review synthesizes current knowledge on cancer genetics, highlighting its importance in developing targeted therapies and enhancing patient outcomes.
Keywords: Epigenetic modifications; Genomic instability; Oncogenic mutations; Precision oncology; Targeted therapy resistance; Tumor microenvironment.
© 2025. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Conflict of interest statement
Declarations. Conflict of interest: There is no conflict of interest between the authors regarding this paper. Ethical approval: Not applicable. Consent of participate: Not applicable. Consent to publish: Not applicable.
Similar articles
-
Advancements in Targeted Therapies and Pharmacogenomics for Personalized Breast Cancer Treatment: The Role of Gene SNPs in Treatment Resistance.Curr Gene Ther. 2025 Jun 27. doi: 10.2174/0115665232373621250618181424. Online ahead of print. Curr Gene Ther. 2025. PMID: 40589001
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List.Cancers (Basel). 2025 Jul 18;17(14):2388. doi: 10.3390/cancers17142388. Cancers (Basel). 2025. PMID: 40723270 Free PMC article. Review.
-
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025. Front Immunol. 2025. PMID: 40777041 Free PMC article.
-
Innovations in cancer treatment: evaluating drug resistance with lab-on-a-chip technologies.Int J Pharm. 2025 Sep 15;682:125936. doi: 10.1016/j.ijpharm.2025.125936. Epub 2025 Jul 5. Int J Pharm. 2025. PMID: 40623610 Review.
References
-
- Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Towards personalized care: unraveling the genomic and molecular basis of sepsis-induced respiratory complications. Arch Clin Toxicol. 2024;6(1):4–15.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous